Company news
Oculis Holding AG news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Oculis Publishes Results of 2025 Annual General Meeting
June 4, 2025
Oculis to Participate in Upcoming June Investor Conferences
June 2, 2025
Oculis Publishes Invitation to the Annual General Meeting
May 8, 2025
Oculis Reports Q1 Financial Results and Provides Company Update
May 7, 2025
Oculis Reports Q1 2025 Financial Results and Provides Company Update
May 7, 2025
Oculis to Present at Upcoming May Investor Conferences
May 6, 2025
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
April 30, 2025
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
April 30, 2025
Oculis Updates Share Capital
April 24, 2025
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
April 16, 2025
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
April 14, 2025
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
April 9, 2025
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
April 9, 2025
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
March 31, 2025
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
March 20, 2025
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
March 14, 2025
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
March 10, 2025
Oculis to Present at Upcoming March Investor Conference
March 4, 2025
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
February 13, 2025
Oculis updates share capital for its existing at-the-market offering program
January 30, 2025
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 5, 2025
Oculis Publishes Notification of Major Changes in Voting Rights
January 3, 2025
Oculis to Present at the Stifel 2024 Healthcare Conference
November 12, 2024
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
November 6, 2024
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
October 20, 2024
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
October 14, 2024
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
October 1, 2024
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
September 18, 2024
Oculis to Present at Upcoming September Investor Conferences
August 28, 2024
Oculis Reports Q2 Financial Results and Provides Recent Company Update
August 26, 2024
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
August 26, 2024
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
August 14, 2024
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
July 29, 2024
Oculis and EURETINA Announces the Ramin Tadayoni Award
June 26, 2024
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
June 9, 2024
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
May 29, 2024
Oculis Holding - Increase in share capital
May 20, 2024
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 7, 2024
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
May 7, 2024
Oculis to Present at Bank of America Global Healthcare Conference
May 5, 2024
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
April 21, 2024
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
April 10, 2024
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
April 9, 2024
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
April 7, 2024
Oculis to Participate at Upcoming April Investor Conferences
April 3, 2024
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
March 17, 2024
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
February 27, 2024
Oculis to Present at Upcoming February Investor Conferences
January 28, 2024
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
January 21, 2024
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
December 19, 2023
Decks
The 5 newest of 15 decks. Every deck is listed under its year.
- Investor Presentation (September 2026)
Investor deck · 43 slides · September 2026
- Investor Presentation (June 2026)
Investor deck · 28 slides · Jun 25, 2026
- Technical Presentation (May 2026)
Technical · 17 slides · May 29, 2026
- Shareholder Meeting (May 2026)
Shareholder meeting · 11 slides · May 13, 2026
- Corporate Update (October 2025)
Corporate update · 15 slides · Oct 6, 2025